Soluble CD26 and CD30 levels in patients with anthroponotic cutaneous leishmaniasis

被引:16
作者
Ajdary, Soheila
Jafari-Shakib, Reza
Riazi-Rad, Farhad
Khamesipour, Ali
机构
[1] Inst Pasteur, Dept Immunol, Tehran 13164, Iran
[2] Gilan Univ Med Sci, Rasht, Iran
[3] Univ Tehran Med Sci, Ctr Res & Training Skin Dis & Leprosy, Tehran, Iran
关键词
anthroponotic cutaneous leishmaniasis; sCD26/sCD30;
D O I
10.1016/j.jinf.2006.12.005
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objective: Leishmania tropica is the causative agent of anthroponotic cutaneous leishmaniasis (CL) in Iran. The disease often heats within a year; however, the non-healing forms of disease are also known. The aim of the present study was the determination of the levels of soluble (s) CD26 and CD30 co-stimulatory molecules in sera of L. tropica-infected individuals. The correlations of sCD26 and sCD30 levels with clinical presentation of the disease were assessed. Methods: The levels of sCD26 and sCD30 were determined by a sandwich enzyme-linked immunosorbent assay in sera from patients with acute and non-heating presentation of disease. Results: The serum I.evel. of sCD26 was significantly higher in non-heating patients than in cases with acute CL (P < 0.001). There was no significant difference in sCD26 Level between patients with acute CL and healthy controls. However, the levels of sCD30 in sera from all L. tropica-infected individuals were higher than controls (P < 0.001). A significant difference was also found in sCD30 level between non-heating cases and patients with acute CL (P < 0.001). Conclusion: These findings suggest sCD30 is more relevant to clinical manifestation of cutaneous teishmaniasis than sCD26. The high sCD26 and sCD30 levels in non-heating patients reflect the presence of mixed Th1- and Th2-type responses in these patients. (c) 2006 The British Infection Society. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:75 / 78
页数:4
相关论文
共 32 条
[1]   Soluble CD26/CD30 levels in visceral leishmaniasis: markers of disease activity [J].
Ajdary, S. ;
Riazi-Rad, F. ;
Jafari-Shakib, R. ;
Mohebbali, M. .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2006, 145 (01) :44-47
[2]   Comparison of the immune profile of nonhealing cutaneous leishmaniasis patients with those with active lesions and those who have recovered from infection [J].
Ajdary, S ;
Alimohammadian, MH ;
Eslami, MB ;
Kemp, K ;
Kharazmi, A .
INFECTION AND IMMUNITY, 2000, 68 (04) :1760-1764
[3]   Mucosal leishmaniasis: in situ characterization of the host inflammatory response, before and after treatment [J].
Amato, VS ;
de Andrade, HF ;
Duarte, MIS .
ACTA TROPICA, 2003, 85 (01) :39-49
[4]   The role of CD30 in atopic disease [J].
Bengtsson, Å .
ALLERGY, 2001, 56 (07) :593-603
[5]   Elevated serum levels of soluble CD30 in patients with atopic dermatitis (AD) [J].
Bengtsson, A ;
Holm, L ;
Back, O ;
Fransson, J ;
Scheynius, A .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1997, 109 (03) :533-537
[6]  
CARVALHO EM, 1985, J IMMUNOL, V135, P4144
[7]   THE CLINICAL AND IMMUNOLOGICAL SPECTRUM OF AMERICAN CUTANEOUS LEISHMANIASIS [J].
CONVIT, J ;
ULRICH, M ;
FERNANDEZ, CT ;
TAPIA, FJ ;
CACERESDITTMAR, G ;
CASTES, M ;
RONDON, AJ .
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1993, 87 (04) :444-448
[8]   PREFERENTIAL EXPRESSION OF CD30 BY HUMAN CD4(+) T-CELLS PRODUCING TH2-TYPE CYTOKINES [J].
DELPRETE, G ;
DECARLI, M ;
ALMERIGOGNA, F ;
DANIEL, CK ;
DELIOS, MM ;
ZANCUOGHI, G ;
VINANTE, F ;
PIZZOLO, G ;
ROMAGNANI, S .
FASEB JOURNAL, 1995, 9 (01) :81-86
[9]   Cutaneous leishmaniasis: Clinical aspect [J].
Dowlati, Y .
CLINICS IN DERMATOLOGY, 1996, 14 (05) :425-431
[10]  
FLEISCHER B, 1994, IMMUNOL TODAY, V15, P181